Inflammasomes in the Urinary Tract: 
A disease based review

By

J. Todd Purves¹* and F. Monty Hughes¹

¹Department of Surgery. Division of Urology: Duke University Medical Center. Durham, NC.

* Correspondence: J Todd Purves; Department of Surgery, Division of Urology, Duke University Medical Center P.O. Box 3831 Durham, NC 27710 (telephone: 1-919-684-6994; FAX: 1-919681-5507; email: todd.purves@duke.edu)

Running Title: Inflammasomes in the urinary tract

Key Words: Inflammasomes, urinary bladder, bladder outlet obstruction, inflammation, cystitis, innate immunity, kidney
Abstract

Inflammasomes are supramolecular structures that sense molecular patterns from pathogenic organisms or damaged cells and trigger an innate immune response, most commonly through production of the pro-inflammatory cytokine IL-1β and IL-18, but also through less understood mechanisms independent of these cytokines. Great strides have been made in understanding these structures and their dysfunction in various inflammatory diseases, lending new insights into urological and renal problems. From a clinical perspective, benign urinary pathology almost universally involves the inflammatory process and understanding how inflammasomes translate etiological conditions (diabetes, obstruction, stones, UTIs, etc.) into acute and chronic inflammatory responses is critical to understanding these diseases at a molecular level. To date, inflammasome components have been found in the bladder, prostate, and kidney and have been shown to be activated in response to several infectious and non-infectious insults. In this review we summarize what is known regarding inflammasomes in both the upper and lower urinary tract and describe several common disease states where they potentially play critical roles.
Introduction

Inflammation plays a major role in disorders of the urinary tract due to its constant exposure to noxious stimuli in urine, continuity with an external surface rich in microbes and significant mechanical stressors such as high pressure and stones. Consequently, there is an interest in understanding inflammatory pathways in urinary tract pathology. Inflammation begins with activation of the innate immune system by infectious or noninfectious (sterile) stimuli and inflammasomes serve as sensors and effectors of such stimuli. In this review, we discuss the importance of inflammasomes in some of the major diseases of the urinary tract.

Inflammasomes

The innate immune system responds to patterns found in components of pathogens (Pathogen Associated Molecular Patterns, PAMPs) or in molecules derived from damaged or dying cells (Danger Associated Molecular Patterns, DAMPs). These patterns are recognized by pattern recognition receptors (PRRs) found in specialized immune cells, epithelia and other tissues.

PRRs are classified into five families (Table 1). Some members of the NLR and HIN-200 families respond to DAMPs or PAMPs by forming supramolecular structures known as inflammasomes, often with adaptor molecules such as apoptosis-associated speck-like protein (ASC). These structures activate the cysteine protease caspase-1 which cleaves pro-interleukin-1β (pro-IL-1β) to IL-1β and pro-IL-18 to IL-18. The mature cytokines are pro-inflammatory and trigger classical components of the inflammatory response. The inflammasome is named after the PRR that organizes it and the best studied of these is the NACHT, LRR and PYD domains-
containing protein 3 (NLRP3) which plays important roles in a wide variety of inflammatory diseases including several urologic pathologies.

Canonical and Non-Canonical Activation of NLRP3 (Figure 1)

As depicted in Figure 1, the NLRP3 inflammasome is activated by canonical and non-canonical pathways (27, 57, 100, 117). In most cell types the canonical pathway requires two steps, priming and activation. For priming, a ligand such as lipopolysaccharide binds to a non-NLR receptor such as TLR4, increasing expression of inflammasome components (NLRP3, ASC, caspase-1 and pro-IL-1β; IL-18 is typically constitutively expressed) (10). Priming also promotes deubiquitination of preexisting NLRP3, thus “licensing” it for activation (47, 81). The second step, activation, is then triggered by events such as extracellular ATP binding to a purinergic receptor, reactive oxygen species (ROSs) or insoluble crystals disrupting the cell membrane. Following this stimulus numerous changes can occur such as potassium efflux from the cell, production of ROS, translocation of NLRP3 to the mitochondria, mitochondrial degradation with release of mDNA and cardiolipin, and lysosomal disruption with release of cathepsins. Not all of these changes occur with all agonists and so the exact steps, and the necessity of those steps in response to a given signal, remain hotly debated. The net result is NLRP3 oligomerization which triggers nucleation of ASC proteins to form long filaments. These filaments interact with pro-caspase-1 which itself forms long filaments off of the ASC. Autoproteolytic maturation of caspase-1 is then triggered by a process known as induced proximity. Active caspase is released from the complex and cleaves pro-IL-1β and pro-IL-18 to their mature forms. Active caspase-1 has recently been shown to cleave gasdermin D (95) and
the n-terminal fragment of this protein is directly responsible for bringing about the lytic cell
death process called pyroptosis (32, 50, 96). Pyroptosis results in the release of the mature IL-1β
and IL-18 cytokines along with DAMPS such as ATP, uric acid and high-mobility group box 1
(HMGB1) that trigger inflammasome activation in neighboring cells and further exacerbate the
developing inflammation. Pyroptotic release of the ASC-containing aggregates (known as ASC-specks) can also mature pro-cytokines in the extracellular space as well as activate pro-caspase-1
within macrophages or other cells once they are re-internalized. Adding to this feed-forward
effect, the n-terminus of gasdermin D itself promotes further NLRP3-dependent activation of
caspase-1 (50). Intriguingly, there may be an additional, perhaps redundant, mechanisms leading
to pyroptosis through the canonical pathway for Shi et al (95) found that resistance to pyroptosis
in bone marrow-derived macrophages from gasdermin D null mice faded with prolonged
inflammasome stimulation by canonical activators.

The NLRP3 inflammasome complex can also be formed and activated by a non-canonical
pathway involving caspase-11 in rodents (caspase-4 and 5 in humans) (27, 44, 57, 86, 107).
These caspases are activated by directly binding LPS or intracellular bacteria. Once activated,
caspase-11 then stimulates the formation and activation of the macromolecular inflammasome
and the events downstream. Interestingly, caspase-11 can directly cleave gasdermin and thus can
induce pyroptosis even in the absence of inflammasome formation (50).

Canonical and Non-canonical Activation Pathways versus Canonical and Non-canonical Effects
Exerted by NLRP3
In addition to canonical and non-canonical mechanisms that activate NLRP3, there are canonical and non-canonical effects exerted by the NLRP3 inflammasome once it is activated. While the overuse of the terms canonical and noncanonical may be somewhat confusing, their use is ingrained in the literature and will be used here for consistency. The canonical and noncanonical pathways of NLRP3 activation are described above whereas canonical effects of NLRP3 imply physiological changes induced by the end products, IL-1β or IL-18. Non-canonical effects are defined as those that do not involve these cytokines regardless of mechanism.

Inflammation in the Urinary Tract

Classification of inflammation within the urinary tract depends on location and underlying etiology. Inflammation of the upper tract includes ureteritis or nephritis where the predominant concern is progression to renal failure. In the lower tract, urethritis, prostatitis or cystitis presents as pain and/or disruptions in normal voiding and storage function (typically increased urinary frequency, urgency and incontinence). Further subdivision of inflammatory pathologies depends on whether the cause is due to pathogens, such as bacterial cystitis or pyelonephritis, or sterile insults such as uric acid in diabetic uropathy or cyclophosphamide in hemorrhagic cystitis.

Inflammasomes in Sterile Pathology of the Upper Urinary Tract
In the upper tract, inflammasome components are found in tubular epithelium, podocytes and immune cells and expression may vary over time (22). For example, Song et al. have shown that NLRP3 and NLRC4 are upregulated with aging while NLRP1 and AIM 2 appear to be stable (22). The increased expression of NLRP3 was found primarily in the glomeruli which may be relevant to progressive glomerulosclerosis or other age-related kidney disorders.

Diabetic Nephropathy

The genesis of diabetes depends on genetic and environmental factors but in the case of type 2 it appears to arise as the result of metabolic-induced inflammation as do subsequent complications including nephropathy. Hyperglycemia causes an influx of glucose into insulin-independent cells (such as kidney tubular epithelial cells), which increases metabolism, ROS production and mitochondrial damage. In turn, these established activators of NLRP3 initiate canonical cytokine production and pyroptosis. Pyroptosis releases a cascade of DAMPs, thus amplifying and perpetuating the response. While the list of potential DAMPs is immense, three are particularly relevant to diabetic nephropathy (109).

Uric Acid as a DAMP

Hyperuricemia is an independent risk factor for nephropathy and uric acid is a well-known DAMP (125). Initially implicated in gout (25), uric acid activates NLRP3 in the kidney. Reducing serum uric acid prevents NLRP3 activation in streptozotocin-induced diabetic rats and helps preserve renal function (111). Kim, et. al. found that, rather than having a direct effect on
the tubular epithelial cells that express NLRP3, there is a complex cross-talk with resident
macrophages (53). When directly exposed to uric acid, renal tubular cells increase expression of
NLRP3 but do not secrete IL-1β. However, uric acid does stimulate these cells to release CXC
Motif Ligand 12 (CXCL12 - a macrophage recruiter) and HMGB1 (a DAMP) which recruits
macrophages, activates their NLRP3 and cause them to release IL-1β. Uric acid also directly
activates the NLRP3 in the recruited macrophage. IL-1β secreted by the macrophages diffuses
back to the tubular epithelial cells to activate NF-kB, priming them for further response. This
example illustrates the complex intracellular communication between immune and epithelial
cells within the kidney.

ATP as a DAMP

Hyperglycemia promotes high metabolism, cell turnover and pyroptosis, all of which
generate extracellular ATP. High glucose also stimulates ATP secretion by renal mesangial cells
(99) further increasing extracellular ATP levels. ATP is a quintessential DAMP that triggers
inflammasome activation by binding to the purinergic receptor P2X7 (63, 84), although the
kidney may be an exception. Chen et al. documented increased P2X4 expression in renal tubule
cells, along with increased urinary IL-1β and IL-18, in 45 diabetic nephropathy patients (15). In
vitro HK-2 cells activate NLRP3 in response to high glucose and this was blocked by P2X4
antagonist, siRNA to P2X4 and the ATP scavenger apyrase. This data implicates ATP as a renal
DAMP with P2X4 as the novel purinergic receptor involved. However, P2X4 can form a
complex with P2X7 to mediate inflammasome activation (39) suggesting a P2X4:P2X7 complex
that might align Chen’s paper with more conventional ideas of inflammasome activation by ATP.

Albumin as a DAMP

Besides serving as a urinary marker for diagnosing diabetic nephropathy, albumin itself appears to act as a DAMP when it comes into contact with renal tubular epithelial cells. Liu, et. al. found that rats subjected to an albumin overload, in the absence of hyperglycemia, increased priming and activation of NLRP3 (61) in these cells. Virtually identical results were detected in vitro when cultured HK-2 cells were exposed to bovine serum albumin (BSA). Thus, while we tend to think of albumin as a prevalent but benign protein, when encountered in the wrong location such as the renal tubules, it can function directly as a DAMP to propagate inflammation and nephropathy.

NLRP3 as a target for diabetic nephropathy

Inflammation becomes a self-perpetuating cycle that persists in the chronic state of diabetes; consequently, NLRP3 is a logical target for protecting the kidney. Yang and colleagues (123) treated diabetic mice with the lectin-like domain of thrombomodulin (THBDD1), an inhibitor of NLRP3 priming and activation, and showed that albuminuria and glomerular sclerosis were decreased while renal function was preserved, even though there was no effect on hyperglycemia or hyperglycosuria. Although the non-specific actions of THBDD1 prohibit drawing specific mechanistic conclusions, the results suggest that targeting the NLRP3 pathway
may be useful independently of, or in conjunction with, blood sugar control. Further argument for this can be found in a clinical observation made by Balasubramaniam et. al. (7) who found that patients with diabetic kidney disease, when treated with the IL-1 receptor antagonist, Anakinra, for acute gout attacks, showed transient improvement in their renal function.

Obstructive Nephropathy and Ischemia

Obstruction in the upper tract occurs from congenital anatomic defects, iatrogenic injury, or mechanical compression by tumors, bladder hypertrophy, or stones. Regardless of etiology, obstruction increases tubular pressures that can damage the kidney over time. Obstruction also decreases renal blood flow and creates a relative hypoxia which brings on an inflammatory state (42). This can present in the clinics as acute renal failure or it can persist chronically and bring about fibrosis and end-stage renal failure. Since inflammasomes act as triggers to initiate an inflammatory response it is not surprising that most studies of its role in obstructive nephropathy have focused on early periods following injury.

Unilateral Ureteral Obstruction (UUO) model

The most frequently utilized animal model for obstructive nephropathy involves ligating a single ureter and then comparing the obstructed kidney to the contralateral, unobstructed one (19, 106). Within days, histological changes indicative of inflammation are apparent that include disruption of tubular integrity, tubular atrophy, infiltration of inflammatory cells, accumulation
of myofibroblasts, and the beginning of extracellular matrix deposition. If the obstruction is not relieved, there is progression of fibrosis and loss of function.

Role of NLRP3 in UUO

The expression and involvement of IL-1β in the UUO-induced inflammatory process suggests a role for NLRP3 (120). Recently, several investigators (80, 108, 115) have compared the inflammatory response between obstructed wild-type and NLRP3−/− mice. Wild-type kidneys display typical signs of NLRP3 priming, activation and inflammation in the acute phase following UUO, which were diminished in NLRP3−/− mice (108, 115), implicating this inflammasome in the response to obstruction. The activity of caspase-1 in the null animals remained low over a two week period, but after this initial lag IL-1β and IL-18 returned to wild type levels (108). This suggests there are redundant pathways for cytokine maturation that may emerge beyond the acute phase of obstruction. Indeed, by 4 weeks tubular damage was similar in the wild-type and NLRP3−/− mice.

Linking the canonical effects of NLRP3 with the functional deficits seen in patients during and immediately following obstructive nephropathy is critically important. Clinically, patients with renal obstruction undergo de-obstructing procedures and this can result in post-obstructive diuresis with dangerous electrolyte imbalances. This is due, in part, to an attenuated expression of aquaporins in the tubules hampering the reabsorption of water and this condition remains until aquaporins can be restored to their normal levels (60). It has been shown that UUO causes an increase in intrarenal angiotensin II (108) and that angiotensin II increases NLRP3 priming and activation (113, 114) resulting in the canonical release of IL-1β. IL-1β then acts on
neighboring cells to decrease aquaporin-2 expression, thus reducing water resorption and causing diuresis (114). Wang, et al. also found that inhibitors of the renin angiotensin system, such as angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and a direct renin inhibitor (DRI), diminished the expression of NLRP3 inflammasome components, reduced IL-1β levels and enhanced aquaporin-2 expression (115). This connection between the renin-angiotensin system and the innate immune system may provide an opportunity for clinical intervention.

Adding to the complexity of NLRP3’s role in UUO is the possible involvement of non-canonical effects (62, 80). For example, Pulskens et al. found that there was actually increased interstitial edema in the obstructed NLRP3−/− mouse kidney (80), an unexpected result since NLRP3 promotes inflammation and edema is a classical inflammatory endpoint. The enhanced edema in the null mouse came from increases in tubular and vascular permeability caused by reductions in components of intracellular junctions. The authors attributed this to non-canonical effects of NLRP3 maintaining basally high levels of claudin and cadherin expression. However, it has also been found that albumin-activated NLRP3 stimulates decreases in claudin-1 and thus should lead to increases in permeability (124). This decrease in claudin-1 was blocked in caspase-1−/− mice, suggesting that the effect on claudin-1 in this model is mediated through canonical mechanisms (124). Consequently, further studies on obstructed models with concurrent blockade of the downstream canonical pathway will be required to definitively conclude whether the NLRP3 preservation of vascular and tubular epithelium in the basal state is a canonical or non-canonical effect.
Finally, ischemia-reperfusion injury (97) is relevant to UUO considering the state of ischemia created by the increased tubular pressure. Using a mouse model of renal artery occlusion, Shigeoka et al. found that NLRP3−/− mice had less inflammation and less tubular injury while preserving renal function (97). However, ASC, caspase-1, IL-1β and IL-18 were not required for this effect suggesting non-canonical effects of NLRP3 in the ischemic kidney.

**DAMPs Released During Obstruction**

Increased pressure and ischemia during obstruction produce DAMPs such as HMGB1, biglycan, hyaluron and many others (3). HMGB1 is a nuclear protein commonly released as a DAMP from many cells, including tubular epithelial cells (82, 119, 122). Blocking its release reduced kidney injury and renal fibrosis during UUO (105). Biglycan is a component of the extracellular matrix (3, 73, 92) present in soluble form at high levels after obstruction but before the infiltration of macrophage (35, 93). It promotes priming and activation of NLRP3 without the need for a co-stimulating factor. Hyaluronan, another component of the ECM, similarly activates the inflammasome during kidney inflammation (3, 92). It is currently unclear which DAMPs are predominant at any given time point after UUO.

**Stone disease- Nephrolithiasis and Crystalline Nephropathy**

Precipitation of insoluble salts from urine results in formation of crystals that manifest extra-renally, as in the case of kidney stones, or intra-renally as seen in oxalosis or gouty nephropathy (6, 103). While the mechanism of injury to the kidney by crystals was traditionally attributed to mechanical obstruction of urine flow, inflammation is emerging as an important
component of this injury (3, 69, 102). Critical to this understanding was the initial discovery that
gout-associated uric acid crystals activated NLRP3 (65), a fact later extended to most, if not all,
crystallopathies such as asbestosis, silicosis and nephrolithiasis (69).

Canonical vs. non-canonical effects and the crystal DAMPs

The canonical effects of NLRP3 activated by crystals are well-established and were, in
fact, used to delineate much of the classical canonical pathway. The crystals themselves can be
composed of numerous agents including uric acid, calcium oxalate, calcium phosphate, cysteine,
adenine, certain drugs or contrast media. We focus on calcium oxalate and cysteine as
representative crystals, having already discussed uric acid in the context of diabetic uropathy.

Calcium oxalate is one of the most clinically important urinary precipitates as it accounts
for the majority of kidney stones and can also be seen in metabolic derangements such as
primary oxaluria and polyethylene glycol toxicity. Mulay and colleagues demonstrated in an
acute model that calcium oxalate crystals initiate injury and cell death in tubular epithelial cells
through obstructive effects and direct physical damage (69, 70). This causes the release of ATP,
and likely many other DAMPs, which triggers activation of the NLRP3 inflammasome in the
nearby dendritic cells, likely through production of ROS (46). Similarly, Knauf et al. found in a
chronic model of oxalate nephropathy that NLRP3\textsuperscript{\textminus/\textminus} mice were protected from progressive renal
failure and death (54). Mice deficient in inflammasome components, IL-1R or IL-18 had
diminished inflammation and tissue injury (70). Therefore, it appears that canonical effects of
NLRP3 are a critical driver of both acute and chronic inflammation induced by calcium oxalate
 crystals
Cystine crystals are a devastating cause of nephrolithiasis in patients with mutations of the CTNS gene (a lysosomal cystine proton cotransporter). In a recent study, Prencipe et al. (79) found that cystine both primed and activated NLRP3 in monocytes. Clinically, their findings correlated with the observation that patients with cystinosis had higher circulating levels of IL-1β and IL-18. Taken together, the NLRP3 pathway constitutes a likely therapeutic target for crystalline nephropathies regardless of the specific type of crystal involved.

Inflammasomes in Sterile Pathology of the Lower Urinary Tract

The Potential Repertoire

Our laboratory has shown that the rat bladder contains seven different PPR’s known to form inflammasomes (NLRP1, 3, 6, 7 and 12, NLRC4 and Aim2) (36). All 7 were present in the urothelia with most concentrated in the layer abutting the lumen. Most were also in the detrusor with little to no expression in the interstitial layer. We have also shown that DAMPs and PAMPs instilled directly into the lumen of the bladder can activate two of the NLRs (NLRP3 and NLRC4) (37). The presence of multiple inflammasome components in the bladder illustrates how critical they are in allowing the immune system to sense a wide variety of stimuli.

Cystitis

Cystitis results from infectious or non-infectious sources. Acute cystitis typically generates distinct symptoms such as increased frequency and urgency and incontinence.
Prolonged inflammation induces fibrotic changes that culminate in organ failure and are thought to contribute to the development of transitional cell carcinomas (104).

Chemical Cystitis

Initial evidence implicating inflammasomes in sterile cystitis comes from studies of cyclophosphamide-induced hemorrhagic cystitis. Acrolein, a metabolic by-product of cyclophosphamide, is stored in the bladder prior to excretion where it acts as the initiator of hemorrhagic cystitis, increasing cytokine release including IL-1β and IL-18 (98). Ribeiro’s group used antiserum to IL-1β (26, 83) and an IL-1 receptor antagonist (59) to demonstrate the importance of this cytokine in this inflammatory response. To investigate a role for inflammasomes we utilized the NLRP3 inhibitor glyburide (58) which blocked cyclophosphamide-induced inflammasome activation, reduced IL-1β and IL-18 secretion, and decreased inflammation (37). Most importantly, inhibition of NLRP3 blocked the functional changes associated with irritative bladder inflammation (increased voiding frequency and decreased voiding volume).

Haldar et al. recently showed that acrolein caused the oxidation of mitochondrial DNA along with a concomitant epigenetic silencing of DNA repair enzymes (28, 29). The oxidized mitochondrial DNA then triggered NLRP3 activation and pyroptosis. The released IL-1β, acting through IGF, induced detrusor smooth muscle hyperplasia which is ultimately thought to bring about the functional changes by reducing bladder compliance. Thus, NLRP3 appears to be a critical mediator of biochemical, histological and physiological inflammation in this common model.
Obstructive Uropathy – partial Bladder Outlet Obstruction (BOO)

BOO results from numerous conditions (e.g. stones, organ prolapse, posterior urethral valves) but the most prevalent is benign prostatic hyperplasia (BPH). Recent studies demonstrate that BOO acutely produces an inflammatory state in the bladder (67, 75) leading to irritative symptoms. Similar to renal fibrosis in obstructive nephropathy, chronic BOO leads to bladder fibrosis (18, 67) that is difficult to treat once established (45). We have recently investigated NLRP3 in a rat model of BOO and found that acutely (12 days) there was increased inflammasome activity, bladder hypertrophy, and inflammation which was reversed with the NLRP3 inhibitor glyburide (38). Physiologically, BOO caused irritative symptoms (increased voiding frequency, decreased voiding volume) that were ameliorated by glyburide. Thus, NLRP3 appears to be a mediator of inflammation in this common condition. Although our study did not assess canonical versus non-canonical effects of NLRP3 during BOO, Kanno et al. found that many of the same inflammatory parameters were reversed in IL-1β−/− mice (48), suggesting a predominate role of the canonical pathway.

The mechanism by which NLRP3 is activated in BOO remains unclear but is likely to be multifactorial. For example, there are several sources of ROS during BOO. Severe and/or prolonged bladder distension restricts blood flow and creates ischemia while emptying the bladder relieves this restriction, causing reperfusion which produces a burst of ROS (121). Thus, voiding cycles in BOO animals create cycles of ischemia/reperfusion. In addition, stronger contraction of the detrusor muscle (to push urine past the obstruction) requires a higher rate of
metabolism resulting in increased production of ROS. DAMPs are also likely involved in BOO, particularly ATP. Increased strength of contraction creates high intravesical pressures and elevated pressure is known to release ATP from urothelia (76). Moreover, pressure has been shown to induce necrosis and/or apoptosis. Necrosis releases large numbers of DAMPs (41) while apoptosis can also be pro-inflammatory under certain circumstances (17). Of course, release of cytokines by pyroptosis further releases DAMPs and propagates the resulting inflammation (57). These observations provide a basis for discerning how NLRP3 coordinates the action of the innate immune system in normal voiding conditions versus its response to pathological pressures as encountered with BOO.

**Interstitial cystitis/Bladder Pain Syndrome**

Interstitial cystitis/bladder pain syndrome is a clinical entity diagnosed by urinary frequency, urgency and pain. Although the etiology is unknown, current theories propose that it is caused by an alteration in the composition of the glycosaminoglycan layer lining the bladder that increases permeability, thereby exposing urinary solutes to the urothelium and triggering an inflammatory reaction (2, 40, 51, 77, 94). Such a scenario strongly suggests that inflammasomes in the urothelium could serve as sensors of those solutes and triggers of the inflammatory reaction. Indeed, significant increases of IL-1β have been detected in the serum of these patients (43). Since the sources of bladder inflammation and pain are likely to vary between patients, identification of a common mediator such as NLRP3 could lead to an effective therapeutic strategy.

**BPH and Prostatitis**
Studies are just beginning to explore inflammasomes in the prostate. Although no study has systematically examined the repertoire present, expression of NLRP1, NLRP3 and AIM2 have been reported (13, 56, 78). Non-neoplastic prostatic pathologies include BPH and prostatitis. While two distinct entities, there is significant clinical overlap and large studies such as MTOPS (Medical Therapy Of Prostatic Symptoms), have implicated a critical inflammatory component in both (87). The NIH consensus on prostatitis (55) lists four distinct types: I. Acute bacterial, II. Chronic bacterial, III. Inflammatory/non-inflammatory chronic and IV. Asymptomatic inflammatory. Given their responsiveness to PAMPs, it is relatively easy to envision the activation of inflammasomes in the prostate by bacteria (Types I and II prostatitis) although this has not been explored. However, two recent reports have examined sterile prostatitis (Type III) induced by chemical injection (carrageenan or formalin) and both detect inflammasome activation, although they implicate NLRP1 over NLRP3 (13, 49). These studies found elevated NLRP1, caspase-1 and IL-1β levels but not NLRP3. Moreover, Kashyap et al. found IL-18 increased relative to IL-1β (49). In a related paper, Hamakawa et al. performed a cDNA microarray analysis on 31,100 genes in BPH patients and found 7 inflammation-related genes upregulated (>2-fold) with IL-18 increased 11.09-fold (30) but no change in IL-1β. These results suggest that in sterile prostatitis, NLRP1 production of IL-18 predominates, with little or no involvement by NLRP3 or IL-1β.

Finally, one study documented AIM2 (which detects DNA) expression in normal prostate with an increase in BPH tissue (78). Although the type of BPH was not defined, AIM2 could be activated in prostate cell lines suggesting the possible involvement of this inflammasome in prostatic disease.
Role of Inflammasomes in Urinary Tract Infections

Infectious Cystitis

The majority of inflammasome-forming PPRs we have found to be present in the urothelium (36) have pathogen-associated ligands, suggesting that they evolved primarily to respond to infectious agents. Infectious cystitis, the second most common type of human infection (9, 33), is caused by viral, mycobacterial, chlamydial, fungal and schistosomal agents although uropathogenic E. coli (UPEC) are responsible for up 80% of community acquired infections (23, 88). UPEC contain many prototypical PAMPs that activate NLRs such as lipopolysaccharide and flagellin. Moreover, IL-1β is among the first cytokines detectable in urine following infection (1) suggesting early activation of inflammasomes during UTIs. Despite the seemingly obvious connection, little is known about the role of inflammasomes in the host defense against infection.

NLRP1, which we have found to reside in the urothelium and detrusor (36), recognizes muramyl dipeptide (21). Muramyl dipeptide is a common peptidoglycan of both gram-negative and gram-positive bacteria but to date no studies have investigated a role for this PAMP or NLRP1 in UTIs. NLRP3, also expressed in the urothelia, responds to hemolysin in addition to LPS (66, 71). Hemolysin is a virulence factor for UPEC and its expression correlates with the pathogens ability to evade host defenses and infect the upper urinary tracts (85). Hemolysin has also been shown to induce pyroptosis in human urothelial cells in part via the activation of the NLRP3 inflammasome through the non-canonical activation pathway (72). Recently, Symington et al. showed in mice that UPEC taken up in macrophages activates NLRP3 and results in protection from infection through an IL-1β-dependent mechanism (101). Interestingly, such
protection appears to be inversely regulated by a key autophagy protein, ATG16L1 (101, 110, 112). Schaale et al. also studied the interaction of UPEC with human and mouse macrophages. Although only certain strains of UPEC activated inflammasomes and pyroptosis (91), the responses differed dependent on species. In mouse macrophages the responses were completely NLRP3-dependent and largely α-hemolysin-dependent while in human macrophages NLRP-3-independent and α-hemolysin-independent pathways were activated as well.

Rat urothelia also express NLRP6 (36), which has no known ligand but is critical in regulating the gut microbiota and mucin production. (8, 14, 20) Studies are just beginning to appreciate the importance of the bladder microbiota and its role in UTIs (11, 34, 118) whereas dysfunctional mucosal barriers have been implicated in many bladder disorders including UTIs and interstitial cystitis (77). Consequently, the role of NLRP6 in UTIs may prove to be an important subject for future studies. Rat urothelia also express NLRP7 (36) which respond to microbial acylated lipopeptides and appears to block intracellular replication of bacteria in human macrophages (52). Since progression from acute UTI to chronic cystitis depends on the establishment of intracellular bacterial communities, (4, 5, 31) targeting this PRR may prove useful for preventing recurrent UTIs. NLRC4 is also expressed and can be activated in the urothelia (36, 37) and is best known for responding to flagellin (24, 68), a critical virulence factor that allows UPEC to migrate upstream in the urinary tract (74). NLRC4 also responds to the type III secretion system (12). UPEC typically express these secretion systems and thus potentially engage NLRC4 in a second way. Finally, urothelia express AIM2 whose ligand is double stranded DNA. AIM2 may therefore engage bacteria that release DNA into the cytoplasm (for example through bacteriolysis (90, 116)) as well as sensing viral DNA in the case of viral cystitis.
Infectious Pyelonephritis

Uropathogen migration into the upper tracts may cause life-threatening pyelonephritis (APN) or acute lobar nephronia (ALN). Chen et al. recently examined single nucleotide polymorphisms (SNPs) in 360 pediatric patients and found that genetic polymorphisms in NLRP3 were related to the patients susceptibility to acute pyelonephritis (APN) and acute lobar nephronia (ALN) (16). This is an important link between mutations in the inflammasome pathways and sensitivity to UTIs. However, the mechanisms by which inflammasomes coordinate the innate immune response to infection in the upper tracts has yet to be formally studied.

Conclusion

Although inflammasomes have only recently been discovered (64), there is considerable evidence that they play important roles in almost all inflammatory diseases and the urinary tract is no exception. Understanding their role will shed significant insight into the importance of inflammation in urologic and renal pathology and potentially identify a central therapeutic target for treating and controlling multiple disorders.

Grants

Research in the Purves Laboratory is supported by the National Institute of Diabetes And Digestive And Kidney Diseases of the National Institutes of Health under Award Number
Figure Legend

Fig.1  Schematic of the canonical and non-canonical pathways by which the NLRP3 inflammasome is activated and elicits an inflammatory response. In the canonical pathway (above the horizontal red line) two steps are required, priming (left of the vertical red line) and activation (right of the vertical red line). The priming step is initiated when, for example, lipopolysaccharide (LPS) from a uropathogen binds to the membrane bound TLR4 receptor. Ligand binding then upregulates the expression of inflammasome components such as pro-IL-1β and the Nod-like receptor, NLRP3, via the NF-kB pathway. Preexisting NLRP3 is also de-ubiquitinated, a necessary step before oligomerization can occur. In the second, activating step, a signal is received in the form of 1) potassium efflux from the cell, 2) generation of reactive oxygen species (ROS), 3) mitochondrial damage with release of mitochondrial DNA and cardiolipin and/or 4) lysosomal disruption release of cathepsin B. During this step, NLRP3 oligomerizes and recruits the adapter protein, apoptosis-associated speck-like protein containing the caspase recruitment domain (ASC). Pro-caspase-1 is recruited to complete the active inflammasome where it is cleaved and released as active caspase-1. The activated caspase-1 then cleaves pro-IL-1β and pro-IL-18 to their active forms. Caspase-1 also cleaves Gasdermin D and the N-terminus of this protein is responsible for inducing pyroptosis. Pyroptosis releases the mature cytokines (and many DAMPSs) through a lytic cell death process. The released pro-
inflammatory cytokines then initiate the inflammatory process while the DAMPs propagate the
inflammation by triggering inflammasome activation in neighboring cells

In the noncanonical pathway, LPS (or other triggering agent) binds directly to caspase-11 which
then facilitates the oligomerization of the NLRP3 inflammasome and subsequent maturation of
cytokines. Caspase-11 can also stimulate pyroptosis by direct cleavage of Gasdermin D.

References

   reviews Immunology 15: 655-663, 2015.
2. Akiyama A, Stein PC, Houshiar A, and Parsons CL. Urothelial cytoprotective activity of Tamm-
   Horsfall protein isolated from the urine of healthy subjects and patients with interstitial cystitis.
3. Anders HJ and Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like
   receptors, and inflammasomes also drive regeneration and fibrosis. Journal of the American Society of
4. Anderson GG, Dodson KW, Hooton TM, and Hultgren SJ. Intracellular bacterial communities of
5. Anderson GG, Martin SM, and Hultgren SJ. Host subversion by formation of intracellular
   nephrolithiasis: a review of pathogenic mechanisms in the light of genetic studies. Am J Nephrol 40: 499-
   506, 2014.
7. Balasubramaniam G, Almond M, and Dasgupta B. Improved renal function in diabetic patients
   growth factor reviews Epub ahead of print, 2014.
    Wu J, Monks BG, Fitzgerald KA, Hornung V, and Latz E. Cutting edge: NF-kappaB activating pattern
    recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3


Table 1. Pattern Recognition Receptor Families.

<table>
<thead>
<tr>
<th>Receptor Family</th>
<th>Acronym</th>
<th>Inflammasome forming members</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toll like receptors</td>
<td>TLRs</td>
<td>none</td>
<td>Cell membrane</td>
</tr>
<tr>
<td>C-type lectins</td>
<td>CTLs</td>
<td></td>
<td>Cell membrane</td>
</tr>
<tr>
<td>Retinoic acid inducible gene-I (RIG-I)-like receptors</td>
<td>RLRs</td>
<td></td>
<td>Intracellular</td>
</tr>
<tr>
<td>HIN-200</td>
<td></td>
<td>AIM2, IFI 16</td>
<td>Intracellular</td>
</tr>
<tr>
<td>Nucleotide binding and oligimerization domain (NOD)-like receptors</td>
<td>NLRs</td>
<td>NLRP1, NLRP2, NLRP3, NLRP6, NLRP7, NLRP12, NLRC4</td>
<td>Intracellular</td>
</tr>
</tbody>
</table>